Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Identification of a new potential mechanism responsible for severe bleeding in myeloma: immunoglobulins bind the heparin binding domain of antithrombin activating this endogenous anticoagulant.

× No keyword cloud information.

13 in total

1. Report of three cases of circulating heparin-like anticoagulants.

Authors: P Llamas; J Outeiriño; J Espinoza; A B Santos; A Román; J F Tomás
Journal: Am J Hematol Date: 2001-08 Impact factor: 10.047

2. A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population.

Authors: V Djordjevic; M Kovac; P Miljic; M Murata; A Takagi; I Pruner; D Francuski; T Kojima; D Radojkovic
Journal: J Thromb Haemost Date: 2013-10 Impact factor: 5.824

Review 3. Circulating heparin-like anticoagulants: report of five consecutive cases and a review.

Authors: A Tefferi; W L Nichols; E J Bowie
Journal: Am J Med Date: 1990-02 Impact factor: 4.965

4. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement.

Authors: S T Olson; J D Shore
Journal: J Biol Chem Date: 1981-11-10 Impact factor: 5.157

5. Neutralization of enoxaparine-induced bleeding by protamine sulfate.

Authors: J Van Ryn-McKenna; L Cai; F A Ofosu; J Hirsh; M R Buchanan
Journal: Thromb Haemost Date: 1990-04-12 Impact factor: 5.249

6. In silico discovery of a compound with nanomolar affinity to antithrombin causing partial activation and increased heparin affinity.

Authors: J Navarro-Fernández; H Pérez-Sánchez; I Martínez-Martínez; I Meliciani; J A Guerrero; V Vicente; J Corral; W Wenzel
Journal: J Med Chem Date: 2012-07-17 Impact factor: 7.446

1. Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine.

Authors: Christopher A Willner; Mohammed M Chisti
Journal: Case Rep Hematol Date: 2018-06-13

2. Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review.

Authors: Haorui Shen; Chao Wu; Lijuan Chen; Run Zhang
Journal: Transl Cancer Res Date: 2020-11 Impact factor: 1.241

2 in total

Identification of a new potential mechanism responsible for severe bleeding in myeloma: immunoglobulins bind the heparin binding domain of antithrombin activating this endogenous anticoagulant.

1. Report of three cases of circulating heparin-like anticoagulants.

2. A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population.

Review 3. Circulating heparin-like anticoagulants: report of five consecutive cases and a review.

4. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement.

5. Neutralization of enoxaparine-induced bleeding by protamine sulfate.

6. In silico discovery of a compound with nanomolar affinity to antithrombin causing partial activation and increased heparin affinity.

Review 7. Bleeding and thrombosis risks in plasma cell dyscrasias.

8. Heparin-like anticoagulant associated with plasma cell myeloma.

9. Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

10. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.

1. Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine.

2. Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review.